Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas
2015 ASCO Annual MeetingPatrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
Related Videos
Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas
Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care...
Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings
Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and l...
Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone rece...
Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies
Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss th...
Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in ca...
